Rob Collin (Dept. of Human Genetics) and Carel Hoyng (Dept. of Ophthalmology), theme Sensory disorders, have received a prestigious award from the Translational Research Acceleration Program of the Foundation Fighting Blindness USA.
This program is dedicated to further translate innovative therapeutic proof-of-concept to patients with retinal disease. With this three-year award, Rob and Carel, together with their team of collaborators, aim to bring antisense oligonucleotide-based splicing modulation therapy for patients with Stargardt disease up to the phase of clinical testing.